B+
Bull case
25%
Probability
Target price
$67.25
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
PBH
Prestige Consumer HealthcareANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$55.20
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$47.38
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-02
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+83.7
Score
AI commentary
Recent news is constructive because of the Q1 beat, raised outlook, acquisitions, and record adjusted free cash flow, but the immediate market reaction appears limited. Social, options, short-interest, employee-sentiment, and post-print analyst-revision data are unavailable; the thesis remains a cautious monitoring view rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-09-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ1 FY2027 beat and raised outlookMedium impact
Q1 revenue rose 6.5% to $265.7 million, organic sales grew 3.2%, adjusted EPS was $0.98, and adjusted free cash flow reached a quarterly record of $83.7 million. Management raised fiscal 2027 revenue guidance to $1.290-$1.315 billion and adjusted EPS guidance to $4.55-$4.65. [#SEC-8K-2026-08-06]
2026-08-14catalystOperations leadership transitionMedium impact
The Senior Vice President of Operations retired effective August 14, 2026. No material disruption is identified in the filing, but the transition warrants near-term execution monitoring. [#8-K-2026-08-14]
2027-03-31catalystAcquisition integration and deleveragingHigh impact
The Breathe Right and LaCorium acquisitions expand the portfolio, while approximately $2 billion of net debt makes integration execution, free-cash-flow conversion, and deleveraging important medium-term drivers. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-02 • Updated nightlySource: Internal modelMethodology